2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FXR

FXR

FXR; NR1H4

FXR

Related Products

PDF 0.6 MB

Farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR regulates the expression of various genes by binding to DNA either as a monomer or a heterodimer with the common partner for NRs, retinoid x receptor (RXR), to FXR response elements. Two known FXR genes exist, the FXRα and FXRβ.

FXR is mainly expressed in liver and small intestine, where it plays an important role in bile acid, lipid, and glucose metabolism. FXR affects several metabolic pathways through its specific target genes, regulating bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, also exhibiting a crucial role in intestinal bacterial growth and liver regeneration.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-160929
    Linafexor
    		Agonist
    Linafexor (CS-0159) is an agonist for farnesoid X receptor (FXR).
    Linafexor
  • HY-W712932
    Chenodeoxycholic Acid-d7
    Chenodeoxycholic Acid-d7 (CDCA-d7) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Chenodeoxycholic Acid-d<sub>7</sub>
  • HY-169192
    BAR-2227
    		Agonist
    BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation.
    BAR-2227
  • HY-N3209
    Nelumol A
    		Agonist
    Nelumol A is a farnesoid X receptor (FXR) agonist.
    Nelumol A
  • HY-175516
    dual FXR/PPARδ agonist-2
    		Agonist
    dual FXR/PPARδ agonist-2 is a FXR/PPARδ dual agonist through hybridation of FXR agonist GW-4064 and PPARδ agonist GW-0742.dual FXR/PPARδ agonist-2 displays potent dual-target activities with a FXR agonistic EC50 of 12.28 nM and 69 % PPARδ activation at 100 nM. dual FXR/PPARδ agonist-2 shows anti-fibrotic effects in pulmonary fibrosis mouse model.
    dual FXR/PPARδ agonist-2
  • HY-W713010
    3-Epideoxycholic acid-d5
    3-Epideoxycholic acid-d5 is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides.
    3-Epideoxycholic acid-d<sub>5</sub>
  • HY-135400S
    Glyco-obeticholic acid-d5
    		Agonist
    Glyco-obeticholic acid-d5 is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist.
    Glyco-obeticholic acid-d<sub>5</sub>
  • HY-121110
    Fexarene
    		Agonist
    Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC50 of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism.
    Fexarene
  • HY-133890
    Tauro-α-muricholic acid
    		Activator
    Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease.
    Tauro-α-muricholic acid
  • HY-168327
    LH10
    		Agonist
    LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models.
    LH10
  • HY-159845
    Lecufexor
    		Agonist
    Lecufexor is a farnesoid X receptor (FXR) agonist.
    Lecufexor
  • HY-135399S
    Tauro-obeticholic acid-d5 sodium
    		Agonist
    Tauro-obeticholic acid-d5 sodium is deuterium labeled Tauro-obeticholic acid. Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
    Tauro-obeticholic acid-d<sub>5</sub> sodium
  • HY-N4294R
    Arjungenin (Standard)
    		Agonist
    Arjungenin (Standard) is the analytical standard of Arjungenin. This product is intended for research and analytical applications. Arjungenin, a pentacyclic triterpenoid compound, is a FXR agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV).
    Arjungenin (Standard)
  • HY-172122
    FXR/HSD17B13 modulator 1
    		Modulator
    FXR/HSD17B13 modulator 1 (compound 6) is a potent modulator of FXR/HSD17B13. FXR/HSD17B13 modulator 1 plays an important roel in metabolic dysfunction-associated steatohepatitis (MASH) research.
    FXR/HSD17B13 modulator 1
  • HY-110066R
    (Z)-Guggulsterone (Standard)
    		Antagonist
    (Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.
    (Z)-Guggulsterone (Standard)
  • HY-76847S1
    Chenodeoxycholic Acid-d9
    		Activator
    Chenodeoxycholic Acid-d9 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Chenodeoxycholic Acid-d<sub>9</sub>
  • HY-117601
    11-Deoxyalisol B
    11-Deoxyalisol B, a triterpene, shows the potent inhibitory activity on Lipopolysaccharide (LPS)-induced nitric oxide (NO) production.
    11-Deoxyalisol B
  • HY-W654353
    Tauro-α-muricholic acid-d4-1 sodium
    		Antagonist
    Tauro-α-muricholic acid-d4-1 (sodium) is deuterium labeled Tauro-α-muricholic acid (sodium). Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal.
    Tauro-α-muricholic acid-d<sub>4</sub>-1 sodium
  • HY-101274A
    (3α,5β,6β,7α)-BAR501
    		98.0%
    (3α, 5β, 6β, 7α)-BAR501 (BAR504-6b) is a compound having cholane scaffolds of formula. (3α, 5β, 6β, 7α)-BAR501 can be used for the research of FXR and TGR5/GPBAR1 mediated diseases.
    (3α,5β,6β,7α)-BAR501
  • HY-B1734
    16-Dehydropregnenolone acetate
    		Antagonist
    16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores.
    16-Dehydropregnenolone acetate
Cat. No. Product Name / Synonyms Application Reactivity